Komori
Kamei (8037) · RiskMitigated

Impairment Risk from Market Deterioration and Weak Performance of Investee Companies

First written in FY2017. 8 of 17 entries say "Mitigated", first in FY2022-Q1. Latest entry: FY2024.

17entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY2019MitigatedFY2023-Q3 – FY20242017: 120172018: 120182019: 120192020: 220202021: 420212022: 320222023: 320232024: 22024
Same theme, other companies

The whole theme swung hardest in 2019: 42 of 86 companies on the "Worse" side.

30 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 145 companies compared. The sentences above are computed from all 145.
Full recordFilings, disclosures and news, newest first
  1. FY2024MitigatedAnnual report

    「Valuation loss on investment securities ¥137 million —」

    The amount of valuation losses on investment securities decreased from ¥137 million in the previous fiscal year to zero in the current fiscal year due to deteriorating market conditions or poor performance by investees.
  2. FY2024-Q3MitigatedAnnual report

    「Valuation loss on investment securities ¥102 million —」

    The valuation loss on investment securities fell from ¥102 million in the same period of the previous year to zero in the current cumulative quarter, reducing the amount of valuation losses recognized.
  3. FY2024-Q2MitigatedAnnual report

    「Valuation loss on investment securities ¥60 million —」

    The valuation loss on investment securities fell from ¥60 million in the same period of the previous year to zero in the current quarter, reducing the amount of valuation losses recognized.
  4. FY2023MitigatedAnnual report

    「Valuation loss on investment securities ¥357 million ¥137 million」

    The valuation loss on investment securities decreased from ¥357 million in the previous year to ¥137 million.
  5. FY2023-Q3MitigatedAnnual report

    「Valuation loss on investment securities ¥410 million ¥102 million」

    The valuation loss on investment securities decreased from ¥410 million in the cumulative period of the same period of the previous year to ¥102 million, reducing the amount of valuation losses due to deteriorating market conditions or poor performance by investees.
  6. FY2023-Q2WorsenedAnnual report

    「Valuation loss on investment securities ¥49 million ¥60 million」

    The valuation loss on investment securities increased from ¥49 million in the same period of the previous year to ¥60 million, and the risk of valuation losses due to deteriorating market conditions or poor performance by investees increased again.
  7. FY2023-Q1MitigatedAnnual report

    「Valuation loss on investment securities ¥50 million —」

    The valuation loss on investment securities fell from ¥50 million in the same period of the previous year to zero in the current quarter, reducing the amount of valuation losses recognized.
  8. FY2022-Q3WorsenedAnnual report

    「Valuation loss on investment securities ¥231 million ¥410 million」

    The valuation loss on investment securities increased from ¥231 million in the cumulative period of the same period of the previous year to ¥410 million, and the risk of valuation losses increased again.
  9. FY2022-Q2MitigatedAnnual report

    「Valuation loss on investment securities ¥196 million ¥49 million」

    The valuation loss on investment securities decreased from ¥196 million in the same period of the previous year to ¥49 million.
  10. FY2022-Q1MitigatedAnnual report

    「Impairment loss on investment securities - 50」

    The valuation loss on investment securities decreased from ¥160 million in the same period of the previous year to ¥50 million.
  11. FY2021RestatedAnnual report

    「Valuation loss on investment securities — ¥230 million」

    A valuation loss of ¥230 million on investment securities was recognized, and the risk of valuation losses due to deteriorating market conditions or poor performance by investees continues.
  12. FY2021-Q3WorsenedAnnual report

    「Valuation loss on investment securities — ¥231 million」

    A valuation loss of ¥231 million on investment securities was recognized, up from ¥196 million disclosed in the previous-quarter filing. The risk of valuation losses on investment securities continues and has increased.
  13. FY2021-Q2MaterialisedAnnual report

    「Valuation loss on investment securities — ¥196 million」

    A valuation loss of ¥196 million on investment securities was recognized, and the risk of valuation losses due to deteriorating market conditions or poor performance by investees materialized.
  14. FY2021-Q1MaterialisedAnnual report

    「Valuation loss on investment securities — ¥160 million」

    A valuation loss of ¥160 million on investment securities was recognized, and the risk of impairment losses on investment securities due to deteriorating market conditions or poor performance by investees materialized.
  15. FY2019RestatedAnnual report

    「For unlisted securities, the determination of whether a decline is temporary is made after comprehensively considering the extent of the decline in net assets, the financial condition of the investee and its future earnings outlook. Additional impairment losses may be required if market conditions deteriorate in the future or the investee performs poorly.」

    The risk of additional impairment losses due to deteriorating market conditions or poor performance by investees continues to be disclosed.
  16. FY2018RestatedAnnual report

    「For unlisted securities, the determination of whether a decline is temporary is made after comprehensively considering the extent of the decline in net assets, the financial condition of the investee and its future earnings outlook. Additional impairment losses may be required if market conditions deteriorate in the future or the investee performs poorly.」

    The risk of additional impairment losses due to deteriorating market conditions or poor performance by investees continues to be disclosed.
  17. FY2017First statedAnnual report

    「For unlisted securities, the determination of whether a decline is temporary is made after comprehensively considering the extent of the decline in net assets, the financial condition of the investee and its future earnings outlook. Additional impairment losses may be required if market conditions deteriorate in the future or the investee performs poorly.」

    For investments including unlisted shares, the company has explicitly disclosed for the first time the risk of additional impairment losses due to deteriorating market conditions or poor performance by investees.
Moved together

"Expanding the pharmacy network and strengthening home healthcare and nursing care businesses" moved the same way as this thread, in the same document, in 6 of its 17 moves.

664444★123456
  1. ★This thread
  2. 1Expanding the pharmacy network and strengthening home healthcare and nursing care businesses6×
  3. 2Initiatives for family pharmacists and pharmacies6×
  4. 3Expanding the overseas and trading businesses and capturing the benefits of overseas M&A4×
  5. 4Risk of Impairment of Fixed Assets4×
  6. 5Impact of COVID-19 on Business Activities and Demand4×
  7. 6Reduced medical visits and fewer pharmacy visitors due to the spread of COVID-194×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Kamei yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.